Abstract: A computer-implemented system and method for entity tracking and identification is provided. A tracker associated with an entity is tracked. Communication is continuously attempted between the tracker and a tracking device associated with an individual in custody of the entity. During one of the attempted communications, an absence of the tracker is determined by identifying a time of the attempted communication and applying a time threshold to the time for the attempted communication. The absence of the tracker is identified when no communication has been established with the tracking device within the time threshold. The entity is classified as missing when the absence of the tracker is determined.

Abstract: A computer-implemented system and method for entity tracking and identification is provided. A tracker associated with an entity is tracked. Communication is continuously attempted between the tracker and a tracking device associated with an individual in custody of the entity. During one of the attempted communications, an absence of the tracker is determined by identifying a time of the attempted communication and applying a time threshold to the time for the attempted communication. The absence of the tracker is identified when no communication has been established with the tracking device within the time threshold. The entity is classified as missing when the absence of the tracker is determined.

Abstract: The present disclose provides methods for forming a microfluidic device. Methods for forming a microfluidic device may comprise providing a microfluidic structure and a film, treating a surface of the microfluidic structure, a surface of the film, or both with a solvent, subsequently pressing the microfluidic structure together with the film under a first heating condition to form the microfluidic device comprising the solvent, and applying a negative pressure to the microfluidic device under a second heating condition, which negative pressure is applied for a time period greater than 30 minutes or at a pressure less than 20 kilopascals (kPa) to remove at least a portion of the solvent. In some aspects, the present disclosure provides devices consistent with the methods herein.

Abstract: The present disclosure provides systems, methods, and devices for processing a biological sample. The device may be a microfluidic device comprising a first channel, at least one chamber, and a second channel. The first channel may be in fluid communication with the chamber. The chamber may be configured to receive a portion of the biological sample from the channel. The second channel may be configured for pressurized outgassing of the chamber, first channel, or both the chamber and first channel.

Abstract: A computer-implemented system and method for entity tracking and identification is provided. A tracker associated with an entity is tracked. Communication is continuously attempted between the tracker and a tracking device associated with an individual in custody of the entity. During one of the attempted communications, an absence of the tracker is determined by identifying a time of the attempted communication and applying a time threshold to the time for the attempted communication. The absence of the tracker is identified when no communication has been established with the tracking device within the time threshold. The entity is classified as missing when the absence of the tracker is determined.

Abstract: A computer-implemented system and method for tracking and authenticating interactions is disclosed. A tracking device is associated with an individual responsible for an entity. Information about the entity is recorded on the tracking device. The tracking device interfaces with at least one further tracking device during an interaction between the responsible individual and a further responsible individual. The information recorded by the tracking device is transferred to the further tracking device and further information is recorded on the further tracking device. The recorded information from each of the tracking devices is compiled as a record for the entity and displayed.

Abstract: Retention devices and methods are provided for drug delivery. The device may include a housing configured for intraluminal deployment into a human or animal subject and at least one reservoir contained within the housing. The at least one reservoir may have an actuation end and a release end and contain at least one drug formulation. A plug may be contained within the at least one reservoir and be moveable from the actuation end toward the release end. The device may also include an actuation system operably connected to the actuation end of the at least one reservoir and configured to drive the at least one drug formulation from the reservoir. The device may also include at least one retention member affixed to the housing and movable between a non-stressed position, a deployment position, and a retention position for retaining the device in an intraluminal location in the subject.

Abstract: A device for delivery of particles into biological tissue includes at least one conduit and a propellant source configured to release a propellant into the conduit. A source of first particles is configured to release first particles into the conduit. A source of second particles is configured to release second particles into the conduit. The second particles comprise a functional material intended to interact with the biological tissue and having a density less than a density of the first particles. The propellant source and the conduit are configured to propel the particles in a collimated stream toward the biological tissue. The first particles are configured to penetrate the biological tissue to create micropores that increase porosity of the biological tissue and the second particles configured to enter the porous biological tissue.

Abstract: Devices and methods are provided for drug delivery. The device may include a housing having a first compartment containing a drug in a dry, solid form, a second compartment containing a liquid carrier for the drug, and an expansion member located within or adjacent to the first or second compartment. The second compartment may be fluidly connectable to the first compartment by a rupturable barrier or mechanical valve. The device may also include an actuation system configured to expand the expansion member to rupture the rupturable barrier or open the mechanical valve and permit the liquid carrier to flow into the first compartment and mix with the drug to form a reconstituted drug solution.

Abstract: An electronic test plate includes a test plate comprising plurality of wells, each well configured to contain a substance to be analyzed. Sensors are arranged to sense characteristics of the substance and to generate sensor signals based on the sensed characteristics over time. The sensors are arranged so that multiple sensors are associated with each well. At least one sensor of the multiple sensors senses a characteristic of the substance that is different from a characteristic sensed by another sensor of the multiple sensors. Sensor select circuitry is arranged on a backplane disposed along the test plate. The sensor select circuitry is coupled to the sensors and enable the sensor signals of selected sensors to be accessed at a data output of the backplane.

Abstract: Retention devices and methods are provided for drug delivery. The device may include a housing configured for intraluminal deployment into a human or animal subject and at least one reservoir contained within the housing. The at least one reservoir may have an actuation end and a release end and contain at least one drug formulation. A plug may be contained within the at least one reservoir and be moveable from the actuation end toward the release end. The device may also include an actuation system operably connected to the actuation end of the at least one reservoir and configured to drive the at least one drug formulation from the reservoir. The device may also include at least one retention member affixed to the housing and movable between a non-stressed position, a deployment position, and a retention position for retaining the device in an intraluminal location in the subject.

Abstract: Retention devices and methods are provided for drug delivery. The device may include a housing configured for intraluminal deployment into a human or animal subject and at least one reservoir contained within the housing. The at least one reservoir may have an actuation end and a release end and contain at least one drug formulation. A plug may be contained within the at least one reservoir and be moveable from the actuation end toward the release end. The device may also include an actuation system operably connected to the actuation end of the at least one reservoir and configured to drive the at least one drug formulation from the reservoir. The device may also include at least one retention member affixed to the housing and movable between a non-stressed position, a deployment position, and a retention position for retaining the device in an intraluminal location in the subject.

Abstract: Devices and methods are provided for drug delivery. The device may include a housing configured for intraluminal deployment into a human or animal subject and first and second reservoirs within the housing, each reservoir having an actuation end, an opposed release end, and a plug moveable from the actuation end toward the release end. First and second drug formulations may be contained in the first and second reservoirs, respectively. The device may also include one or more actuation systems configured to drive the first and second plugs so as to drive the first and second drug formulations from the first and second reservoirs. The housing may include a porous membrane sidewall in fluid communication with the release ends of the first and second reservoirs, the porous membrane sidewall being configured to distribute the first and second drug formulations driven from the first and second reservoirs.

Abstract: What is disclosed is a system and method for representing a subject's state of mind given a plurality of physiological inputs. In one embodiment, a vector of physiological features is received. The vector of physiological features is provided to a psychophysiological model which comprises a plurality of models which fit the physiological features to psychological quantities, each representing a different state of mind. In a manner more fully disclosed herein, the psychological quantities are then aggregated to obtain an aggregate output that is representative of the subject's overall state of mind. Once the subject's state of mind has been represented, remedial action can then be taken.

Abstract: An electronic test plate includes a test plate comprising plurality of wells, each well configured to contain a substance to be analyzed. Sensors are arranged to sense characteristics of the substance and to generate sensor signals based on the sensed characteristics over time. The sensors are arranged so that multiple sensors are associated with each well. At least one sensor of the multiple sensors senses a characteristic of the substance that is different from a characteristic sensed by another sensor of the multiple sensors. Sensor select circuitry is arranged on a backplane disposed along the test plate. The sensor select circuitry is coupled to the sensors and enable the sensor signals of selected sensors to be accessed at a data output of the backplane.

Abstract: A device for delivery of particles into biological tissue includes at least one conduit and a propellant source configured to release a propellant into the conduit. A source of first particles is configured to release first particles into the conduit. A source of second particles is configured to release second particles into the conduit. The second particles comprise a functional material intended to interact with the biological tissue and having a density less than a density of the first particles. The propellant source and the conduit are configured to propel the particles in a collimated stream toward the biological tissue. The first particles are configured to penetrate the biological tissue to create micropores that increase porosity of the biological tissue and the second particles configured to enter the porous biological tissue.

Abstract: Devices and methods are provided for drug delivery. The device may include a housing configured for intraluminal deployment into a human or animal subject and first and second reservoirs within the housing, each reservoir having an actuation end, an opposed release end, and a plug moveable from the actuation end toward the release end. First and second drug formulations may be contained in the first and second reservoirs, respectively. The device may also include one or more actuation systems configured to drive the first and second plugs so as to drive the first and second drug formulations from the first and second reservoirs. The housing may include a porous membrane sidewall in fluid communication with the release ends of the first and second reservoirs, the porous membrane sidewall being configured to distribute the first and second drug formulations driven from the first and second reservoirs.

Abstract: Devices and methods are provided for fluid delivery. The device may include a housing having an outer surface which includes a porous membrane, a fluid reservoir disposed in the interior region of the main housing and formed at least in part by a wall structure, a puncture mechanism operable to puncture the wall structure and form a fluidic path between the fluid reservoir and one or more channels in fluid communication with the porous membrane, and a positive displacement mechanism operable, following puncture of the wall structure, to drive a fluid out of the fluid reservoir, through the one or more channels, and into the porous membrane.

Abstract: Devices and methods are provided for drug delivery. The device may include a housing configured for intraluminal deployment into a human or animal subject and first and second reservoirs within the housing, each reservoir having an actuation end, an opposed release end, and a plug moveable from the actuation end toward the release end. First and second drug formulations may be contained in the first and second reservoirs, respectively. The device may also include one or more actuation systems configured to drive the first and second plugs so as to drive the first and second drug formulations from the first and second reservoirs. The housing may include a porous membrane sidewall in fluid communication with the release ends of the first and second reservoirs, the porous membrane sidewall being configured to distribute the first and second drug formulations driven from the first and second reservoirs.

Abstract: Devices and methods are provided for drug delivery. The device may include a housing configured for intraluminal deployment into a human or animal subject and first and second reservoirs within the housing, each reservoir having an actuation end, an opposed release end, and a plug moveable from the actuation end toward the release end. First and second drug formulations may be contained in the first and second reservoirs, respectively. The device may also include one or more actuation systems configured to drive the first and second plugs so as to drive the first and second drug formulations from the first and second reservoirs. The housing may include a porous membrane sidewall in fluid communication with the release ends of the first and second reservoirs, the porous membrane sidewall being configured to distribute the first and second drug formulations driven from the first and second reservoirs.